Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8(+) T cells against SARS-CoV-2 variants

Recombinant vesicular stomatitis virus (rVSV) vaccines expressing spike proteins of Wuhan, Beta, and/or Delta variants of SARS-CoV-2 were generated and tested for induction of antibody and T cell immune responses following intramuscular delivery to mice. rVSV-Wuhan and rVSV-Delta vaccines and an rVS...

Descripción completa

Detalles Bibliográficos
Autores principales: Parham, Kate A., Kim, Gyoung Nyoun, Richer, Connor G., Ninkov, Marina, Wu, Kunyu, Saeedian, Nasrin, Li, Yue, Rashu, Rasheduzzaman, Barr, Stephen D., Arts, Eric J., Haeryfar, S.M. Mansour, Kang, C. Yong, Troyer, Ryan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970654/
https://www.ncbi.nlm.nih.gov/pubmed/36915805
http://dx.doi.org/10.1016/j.isci.2023.106292
_version_ 1784897951170035712
author Parham, Kate A.
Kim, Gyoung Nyoun
Richer, Connor G.
Ninkov, Marina
Wu, Kunyu
Saeedian, Nasrin
Li, Yue
Rashu, Rasheduzzaman
Barr, Stephen D.
Arts, Eric J.
Haeryfar, S.M. Mansour
Kang, C. Yong
Troyer, Ryan M.
author_facet Parham, Kate A.
Kim, Gyoung Nyoun
Richer, Connor G.
Ninkov, Marina
Wu, Kunyu
Saeedian, Nasrin
Li, Yue
Rashu, Rasheduzzaman
Barr, Stephen D.
Arts, Eric J.
Haeryfar, S.M. Mansour
Kang, C. Yong
Troyer, Ryan M.
author_sort Parham, Kate A.
collection PubMed
description Recombinant vesicular stomatitis virus (rVSV) vaccines expressing spike proteins of Wuhan, Beta, and/or Delta variants of SARS-CoV-2 were generated and tested for induction of antibody and T cell immune responses following intramuscular delivery to mice. rVSV-Wuhan and rVSV-Delta vaccines and an rVSV-Trivalent (mixed rVSV-Wuhan, -Beta, -Delta) vaccine elicited potent neutralizing antibodies (nAbs) against live SARS-CoV-2 Wuhan (USAWA1), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529) viruses. Prime-boost vaccination with rVSV-Beta was less effective in this capacity. Heterologous boosting of rVSV-Wuhan with rVSV-Delta induced strong nAb responses against Delta and Omicron viruses, with the rVSV-Trivalent vaccine consistently effective in inducing nAbs against all the SARS-CoV-2 variants tested. All vaccines, including rVSV-Beta, elicited a spike-specific immunodominant CD8(+) T cell response. Collectively, rVSV vaccines targeting SARS-CoV-2 variants of concern may be considered in the global fight against COVID-19.
format Online
Article
Text
id pubmed-9970654
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99706542023-02-28 Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8(+) T cells against SARS-CoV-2 variants Parham, Kate A. Kim, Gyoung Nyoun Richer, Connor G. Ninkov, Marina Wu, Kunyu Saeedian, Nasrin Li, Yue Rashu, Rasheduzzaman Barr, Stephen D. Arts, Eric J. Haeryfar, S.M. Mansour Kang, C. Yong Troyer, Ryan M. iScience Article Recombinant vesicular stomatitis virus (rVSV) vaccines expressing spike proteins of Wuhan, Beta, and/or Delta variants of SARS-CoV-2 were generated and tested for induction of antibody and T cell immune responses following intramuscular delivery to mice. rVSV-Wuhan and rVSV-Delta vaccines and an rVSV-Trivalent (mixed rVSV-Wuhan, -Beta, -Delta) vaccine elicited potent neutralizing antibodies (nAbs) against live SARS-CoV-2 Wuhan (USAWA1), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529) viruses. Prime-boost vaccination with rVSV-Beta was less effective in this capacity. Heterologous boosting of rVSV-Wuhan with rVSV-Delta induced strong nAb responses against Delta and Omicron viruses, with the rVSV-Trivalent vaccine consistently effective in inducing nAbs against all the SARS-CoV-2 variants tested. All vaccines, including rVSV-Beta, elicited a spike-specific immunodominant CD8(+) T cell response. Collectively, rVSV vaccines targeting SARS-CoV-2 variants of concern may be considered in the global fight against COVID-19. Elsevier 2023-02-28 /pmc/articles/PMC9970654/ /pubmed/36915805 http://dx.doi.org/10.1016/j.isci.2023.106292 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Parham, Kate A.
Kim, Gyoung Nyoun
Richer, Connor G.
Ninkov, Marina
Wu, Kunyu
Saeedian, Nasrin
Li, Yue
Rashu, Rasheduzzaman
Barr, Stephen D.
Arts, Eric J.
Haeryfar, S.M. Mansour
Kang, C. Yong
Troyer, Ryan M.
Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8(+) T cells against SARS-CoV-2 variants
title Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8(+) T cells against SARS-CoV-2 variants
title_full Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8(+) T cells against SARS-CoV-2 variants
title_fullStr Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8(+) T cells against SARS-CoV-2 variants
title_full_unstemmed Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8(+) T cells against SARS-CoV-2 variants
title_short Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8(+) T cells against SARS-CoV-2 variants
title_sort monovalent and trivalent vsv-based covid-19 vaccines elicit neutralizing antibodies and cd8(+) t cells against sars-cov-2 variants
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970654/
https://www.ncbi.nlm.nih.gov/pubmed/36915805
http://dx.doi.org/10.1016/j.isci.2023.106292
work_keys_str_mv AT parhamkatea monovalentandtrivalentvsvbasedcovid19vaccineselicitneutralizingantibodiesandcd8tcellsagainstsarscov2variants
AT kimgyoungnyoun monovalentandtrivalentvsvbasedcovid19vaccineselicitneutralizingantibodiesandcd8tcellsagainstsarscov2variants
AT richerconnorg monovalentandtrivalentvsvbasedcovid19vaccineselicitneutralizingantibodiesandcd8tcellsagainstsarscov2variants
AT ninkovmarina monovalentandtrivalentvsvbasedcovid19vaccineselicitneutralizingantibodiesandcd8tcellsagainstsarscov2variants
AT wukunyu monovalentandtrivalentvsvbasedcovid19vaccineselicitneutralizingantibodiesandcd8tcellsagainstsarscov2variants
AT saeediannasrin monovalentandtrivalentvsvbasedcovid19vaccineselicitneutralizingantibodiesandcd8tcellsagainstsarscov2variants
AT liyue monovalentandtrivalentvsvbasedcovid19vaccineselicitneutralizingantibodiesandcd8tcellsagainstsarscov2variants
AT rashurasheduzzaman monovalentandtrivalentvsvbasedcovid19vaccineselicitneutralizingantibodiesandcd8tcellsagainstsarscov2variants
AT barrstephend monovalentandtrivalentvsvbasedcovid19vaccineselicitneutralizingantibodiesandcd8tcellsagainstsarscov2variants
AT artsericj monovalentandtrivalentvsvbasedcovid19vaccineselicitneutralizingantibodiesandcd8tcellsagainstsarscov2variants
AT haeryfarsmmansour monovalentandtrivalentvsvbasedcovid19vaccineselicitneutralizingantibodiesandcd8tcellsagainstsarscov2variants
AT kangcyong monovalentandtrivalentvsvbasedcovid19vaccineselicitneutralizingantibodiesandcd8tcellsagainstsarscov2variants
AT troyerryanm monovalentandtrivalentvsvbasedcovid19vaccineselicitneutralizingantibodiesandcd8tcellsagainstsarscov2variants

Ejemplares similares